on behalf of the members of the Swiss IBD Cohort Study Group
Introduction
Inflammatory bowel disease (IBD) as chronic progressive inflammatory conditions are associated with lifelong morbidity and increased mortality [1, 2] . Patients with IBD have a high resource consumption, resulting in considerable costs for the healthcare system [3] [4] [5] . Odes et al. [5] presented an estimate of the cost of healthcare in IBD patients in a cohort of eight European countries and Israel. Increased expenditure was influenced largely by country, diagnosis and hospitalization. There were more costs for medical than for surgical hospitalization [5] .
During the last decade, significant advances in the therapeutic potential of both Crohn' s disease (CD) and ulcerative colitis (UC) have been made. A global therapeutic strategy, particularly for CD, has been developed following two options: bottom-up and topdown. The top-down strategy is based on the early use of intensive and costly therapy (currently biologics with or without immunosuppressants) to maintain a good quality of life starting with the first flare-up of the disease and to also prevent the disease from becoming chronic [6] . A recent retrospective and prospective single-centre study identified three clinical factors (age younger than 40 years, presence of perianal disease and initial requirement for steroids) predicting a disabling course of CD [7] . In a healthcare system with sparse resources, besides effective clinical judgement, resource consumption also influences clinical decision-making. Reliable clinical predictors for high resource consumption might help guide physicians and other healthcare professionals in decision-making on IBD therapy. Using data from the population-based Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), the aim of this study was to determine the health resource consumption defined as hospitalization days and medical consultations separately for patients with CD and UC. We further sought to identify clinical predictors for the resource consumption.
Materials and methods

Patient recruitment
The study population included IBD patients participating in the nationwide SIBDCS without restrictions on the basis of age, sex or national origin. Patients must have been diagnosed at least 4 months before inclusion or must have had at least one recurrence to be eligible for participation in the study. The SIBDCS is a multicentre prospective observational population-based study. The SIBDCS was established in 2003 and extended to include all parts of Switzerland in 2006, currently including six major IBD centres, including five university hospitals, as well as many district hospitals and gastroenterology private practices. Patients are followed up once a year, using both a physician and a patient questionnaire. Details of the study design have been published previously [8] . The primary objectives of the SIBDCS are to (i) provide up-to-date epidemiological data (e.g. prevalence, incidence, clinical course of IBD) and to investigate the risk factors associated with favourable or unfavourable evolution of the course of the disease; (ii) document medical care provided to the patient to assess appropriateness of care; (iii) evaluate current health resource consumption (direct and indirect costs) for IBD patients and the influence of new biologic therapies to optimize costs and public health policies for chronic diseases; and (iv) study psychosocial aspects linked to the disease by seeking predictors associated with IBD exacerbations [8] .
Study design Endpoints
The endpoints of our study were number of hospitalization days and number of outpatient visits for IBD. Hospitalization days within 12 months before inclusion in the cohort were compared with hospitalization days before 1-year follow-up. Outpatient visits 3 months before inclusion were compared with outpatient visits 3 months before 1-year follow-up. All analysed data on resource consumption in patients with CD and UC were only IBD-related. The utilization of resource consumption was measured by self-reporting of the patients. This method has been evaluated and validated for chronic diseases by several studies [9, 10] . The self-reporting studies suggest a time frame for self-reporting that is valid until 6 months for outpatient visits and up to 1 year for hospitalization. It is shown that these data can be extrapolated for 1 year [11] . In our study, for outpatient visits, we chose a time frame of 3 months. For hospitalization, a longer time frame (1 year) could be chosen because these data were validated by the study nurses. A standardized plausibility test of data collection was carried out by the statistical centre. These outcome parameters were assessed to reflect resource consumption of IBD patients in the Swiss healthcare system (direct medical costs).
Predictors
The selection of potential predictors was based on a panel of five Swiss IBD experts and literature review. General demographic variables included sex and age (10 year groups). Disease-specific variables included disease duration (defined as the time between diagnosis and enrolment), the presence of fistulas (only for CD patients) and elevated C-reactive protein (CRP) level (Z 7 mg/l). Disease activity was assessed using both the Crohn's disease activity index for CD and the modified Truelove-Witts severity index for UC [12] . Disease was defined as active if the Crohn's disease activity index score was higher than 150 points or if the modified Truelove-Witts severity index score was higher than 10 points. Drug use was evaluated, including steroids (including budesonide), biologics (infliximab, adalimumab, certolizumab pergol), antibiotics, immunosuppressants and 5-aminosalicylic acid (ASA). In Switzerland, infliximab infusions are administered to IBD patients with stable disease in an outpatient setting because of the tariff system. Only in patients with a severe disease that needs hospitalization is infliximab administered in hospital. Extra-intestinal manifestations (EIM) were surveyed by physicians. In addition, smoking habits and depressive symptomatology (no, mild, moderate and severe) were included in the analysis. To assess the level of depressive symptoms, we used the depression subscale of the Hospital Anxiety and Depression Scale consisting of seven items that participants rated on a four-point Likert scale from 0 to 3 (total score 0-21) [13] . Patients meeting a cut-off of at least 8 were defined as having clinically relevant levels of depressive symptoms (i.e. depression).
Data analysis
Our analyses included the total group of 1187 patients who were included between July 2006 and July 2008. At the time of our analysis, 1-year follow-up data were available for 794 patients. A patient who is 'supposed lost to follow-up' was defined as a patient who did not reply to any kind of questionnaire in the past 18 months. Patients were defined to be 'definitively lost to follow-up' if they had completed the STOP sheet, as they then definitely left the cohort.
Descriptive statistics were used to depict patients' characteristics. First, we analysed the association between potential predictors and diagnosis (CD vs. UC) both at enrolment and at the first follow-up visit to determine whether there were significant differences between the two diseases. The bivariate relationship between potential predictors and the outcome parameters hospitalization days and number of medical consultations was assessed using Fisher's exact test for dichotomous variables and the Mann-Whitney U-test for continuous variables.
The multivariate relationship was assessed by regression analyses. We used negative binomial regression for number of outpatient visits (count data with a large variance) compared with mean (overdispersed) and zeroinflated Poisson (ZIP) regression for hospitalization days (count data with a large number of zero values). Binary endpoints (hospitalization yes/no and outpatient visits yes/no) were analysed using backward logistic regression starting with all potential predictors selected through the literature and clinical experts. For all regression analyses, we calculated adjusted odds ratios (OR) with 95% confidence intervals. A P-value of less than 0.05 was considered statistically significant. The analyses were carried out using SAS 9.1 (SAS Institute Inc, Cary, North Carolina, USA) and Stata/SE 11.1 Software (StataCorp LP, College Station, Texas, USA). Goodness of fit was assessed and compared by different criteria (Vuong test, McFadden adjusted-R 2 , Akaike information criterion and Bayesian information criterion) to determine the appropriate regression models.
Ethical considerations
This cohort study was approved by all local ethics committees. All patients provided written informed consent before enrolment into the SIBDCS.
Results
Our analyses included the total group of 1187 patients who were included in the SIBDC between July 2006 and July 2008. A total of 1.9% of patients were supposed lost to follow-up; 0.1% of patients were definitively lost to follow-up within the data extraction interval. Table 1 shows the demographic and disease-specific patient characteristics of 1178 patients at enrolment (58.9% CD, 41.1% UC). Overall, 46.1 and 49.8% of the patient population with CD and UC, respectively, were men.
Patient characteristics
Disease-specific distribution of predictors
The distribution of preselected predictors (e.g. smoking, steroids, use of biologics, use of ASA, use of immunosuppressants, disease activity, presence of EIM and disease duration, depression etc., cf. Table 2 ) was significantly different among both disease groups at enrolment of follow-up patients ( Table 2 ). Therefore, further analyses were stratified by diagnosis, and all results are reported separately for CD and UC.
Resource consumption Hospitalization related to inflammatory bowel disease
Fifteen per cent of CD patients and 12.3% of UC patients were hospitalized for at least 1 day during the last 12 months before the first follow-up ( Table 3 ). The mean (±SD) number of hospitalization days during the last 12 months was 2.0 (±8.8) and 1.5 (±6.1) in CD and UC, respectively ( Table 3 ). Because of logistical reasons, a specific differentiation between the reasons of hospital admission was not possible at the time of this analysis.
Outpatient visits related to inflammatory bowel disease
The mean (±SD) number of outpatient visits (during the last 3 months before follow-up) was 2.3 (±3.2) and 2.1 (±3.6) in CD and UC, respectively (Table 3) . At enrolment, most consultations for IBD were at private practices. For CD, there were 936 outpatient visits at gastroenterologists/surgeons and 752 at general practitioners. For UC, there were 634 outpatient visits at gastroenterologists/surgeons and 534 at general practitioners. There were fewer consultations at hospitals (566 and 355 consultations in CD and UC, respectively). 
Use of medication at follow-up
The use of medication during follow-up is shown in Table 4 . Almost one-third of all patients with IBD were not on medication. Overall, 27.2 and 13.9% of patients with CD and UC, respectively, were on immunosuppressants (azathioprine) only. A total of 17.8% of patients with CD and 3.3% of patients with UC were on biologics only (without any other medication) ( Table 4 ).
Predictors for hospitalization In Crohn's disease
Out of the preselected predictors, the following three predictors were statistically significant predictors for hospitalization days in follow-up patients with CD: use of biologics at enrolment, fistula, and disease activity (each P < 0.0001) ( Table 5 ).
In ulcerative colitis
In terms of hospitalization days, the following predictors were statistically significant: use of biologics, CRP at enrolment, smoke quitters (smoking at diagnosis), age and sex (P = 0.0167, 0.0003, 0.0003, 0.0076 and 0.0175, respectively) ( Table 5 ). In terms of hospitalization days among patients with IBD, the ZIP regression model fitted all outcomes the best.
Predictors for outpatient visits In Crohn's disease
In terms of the number of outpatient visits, age, sex, use of steroid therapy and use of biologics at enrolment were statistically significant predictors (P = 0.0368, 0.0230, 0.0002 and 0.0003, respectively) ( Table 5 ). 
In ulcerative colitis
In terms of the number of outpatient visits, disease activity and use of immunosuppressants at enrolment were statistically significant predictors (P = 0.0009 and 0.0017, respectively) ( Table 5 ).
Multivariate analysis
The negative binominal model was found to be the best model for outpatient visits in both diseases and confirmed a very good fit in the terms of concordance of observed and predicted probability. ZIP regression showed a good fit for modelling hospitalization days ( Table 5 ). Figure 1 summarizes the adjusted OR with 95% confidence interval of predictors for hospitalization days and outpatient visits, separately for CD and UC. For patients with CD, the most significant predictors for Results of negative binomial regression. 
Discussion
Costly therapies in IBD in a setting of healthcare systems with sparse resources are increasingly forcing physicians to consider not only clinical judgement but also resource consumption in their decision-making. Our study analysed factors predicting hospitalization and outpatient visits as important clinical issues of health resource consumption in patients with IBD (CD and UC) on the basis of a nationwide IBD cohort study in Switzerland. Our analyses showed that use of biologics, fistula and activity of disease were predictors for hospitalization days in CD patients. Age, sex, steroid therapy at enrolment and use of biologics were predictors for medical consultations in CD patients. A recent French retrospective and prospective single-centre study identified three factors predicting a disabling course of CD, which were age younger than 40 years, presence of perianal disease and initial requirement for steroids [7] . The course of CD within the first 5 years of the disease was categorized as disabling when at least one of the criteria of clinical severity, conventionally predefined, was present. Two of the three above-mentioned predictive markers (perianal lesions, need for steroid for first flareup), but not age younger than 40 years were confirmed and validated in a Belgian study [14] .
It is well known that patients with IBD have a high resource consumption, with considerable costs for the healthcare system [3] [4] [5] . In 2006, Odes et al. [5] reported the mean annual costs of CD and UC among eight European countries and Israel as EUR 2548 and EUR 1524 per patient-year. Our data on resource consumption are well comparable with the results of the European IBD cohort study [5] . The mean hospitalization rates of IBD patients in Switzerland (1.5 and 2.0 hospital days per patient-year for UC and CD, respectively) are within the range of those in European countries that participated in the European IBD cohort [5] (range of hospital days per patient-year 0.4-3.5 and 0.9-6 in UC and in CD, respectively).
Our analyses showed that patients with CD treated with biologics had more hospitalization days as well as more medical consultations. Of course, we have to consider that biologics are mainly used in patients with more severe disease (i.e. confounding by indication) and therefore it needs to be clearly emphasized that no causal conclusions can be derived from this result. As hospitalization is a costly endeavour, it would be of considerable interest to determine whether biological therapy can significantly reduce hospitalization. Similar to the results of our study, a recent Canadian populationbased study found increased hospitalization within the first 6 months and no reduction within the first 12 months after initiation of biological therapy in patients with CD [15] . In this study, patients initiated on biologics took at least 18 months to achieve comparable resource utilization in terms of hospitalization and 6 months to achieve comparable outpatient visits compared with other treated patients with CD [15] .
Whereas most studies considered resource consumption in CD or IBD (CD and UC combined), there are no data to the best of our knowledge on predictive factors for health resource consumption in UC in terms of hospitalization and outpatient visits. This study offers a unique insight into the utilization of hospitalization and outpatient visits as it uses data from a large ongoing cohort study including patients with CD and UC. The analysis was further stratified by diagnosis (CD; UC) as the distribution of various preselected potential predictors such as smoking, use of steroids, use of biologics, use of ASA, use of immunosuppressants, disease activity, presence of EIM and disease duration differed significantly among both diseases. This concept is supported by other studies on CD and UC showing that health resource consumption differs between the two diseases [5] . For UC, age, sex, CRP, use of biologics and smoking cessation were significant predictors for hospitalization days; disease activity and use of immunosuppressants at enrolment were significant predictors for the number of outpatient visits. Our data confirm results from the published literature [16, 17] suggesting that new smokers might be 'protected' as the rate of hospitalization days is smaller in this group of UC patients [OR 0.56 (0.31-1.01); P = 0.052, cf. Table 5 ]. It is also known that smoking is associated with a less aggressive disease course in UC [16, 17] .
The predicted and observed probabilities of the outcomes by each regression model (i.e. Poisson, negative binominal, ZIP and zero-inflated negative binominal) were congruent, emphasizing a good fit of our regression models and the high predictive value of the significant factors for modelling health resource consumption of IBD patients on the basis of data from the SIBDCS. As soon as further patient data become available, the results will be updated and this will increase the power of our analyses. Future studies from the SIBDCS may additionally allow us to evaluate the direct costs in IBD of hospitalization and outpatient care as important issues of resource consumption.
The findings of our study need to be interpreted within the limitations of the SIBDCS. In this analysis, we focused on hospital days and outpatients as the main markers of resource consumption. The SIBDCS is a comprehensive study on epidemiological data, clinical, psychological and social aspects and on resource consumption in IBD. However, such large studies as the SIBDCS have to trade off completeness of information, feasibility and costs. Our study was focused on hospital days and outpatient visits, and not all cost-relevant data (costs of drugs, costs of laboratory, etc.) were included. A special analysis of other comorbid-illnesses was not carried out in this study. However, the mean age of patients with CD was 41.8 years and that of patients with UC was 42.6 years. Therefore, we assume that the influence of possible comorbid diseases would not have a high impact on the health state. Many of the available data were gathered from patient reports that themselves may contain information bias (in particular recall bias). However, all variables were validated and compared with physician questionnaires whenever possible. As in all observational studies, causal interpretation of predictor effects is hampered by confounding. Although many variables were adjusted in multivariate analyses, uncertainty remains as to whether additional variables were causally involved in the causal web of the disease course, leading to residual confounding. Therefore, we have to emphasize that all effects must be interpreted carefully as statistical predictors rather than causal factors. However, these predictors may be useful to guide clinicians and other medical decision makers (hospital managers, Federal Offices for Health) on actions and decisions involving resource consumptions and efficient disease management. Furthermore, comparison of crosssectional and follow-up data might be limited as not only correlations but also patient populations differed because of fewer inclusions (missing values and dropouts). Beyond this, we also considered the issue of selection bias. Selection bias by inclusion results from the fact that the population is restricted to patients with IBD. In addition, these patients have to fulfil various inclusion criteria to participate in the study. Selection bias also includes loss of follow-up and missing data that affect the results of statistical analyses. To ensure that analyses of cross-sectional and follow-up data were comparable, patient characteristics at follow-up and at enrolment were analysed and showed almost no differences. Our study analysed resource consumption within the first year of follow-up. As shown by Odes [18] , there is a tendency towards higher resource consumption within the first years after the inclusion of IBD patients (patients are included often after an acute flare). This cohort effect might have biased our results.
In further studies, the use of time-dependent data and inclusion of genetics should be analysed on the basis of the SIBDCS. Furthermore, a decision-analytic model [19] predicting long-term clinical and economic consequences could be developed. This model could be applied to several therapeutic strategies in patients with IBD within health technology assessments guiding clinical guideline developers and health policy decision makers.
Conclusion
Data of the Swiss IBD cohort study on resource consumption showed a considerable disease burden of IBD for the healthcare system. This study identified several highly significant and reliable clinical predictors for hospitalization and outpatient visits for CD and UC separately that can be used as a warning system, thus enabling patients and physicians to better predict the course of these diseases and ideally prevent adverse outcomes through effective interventions. In terms of resource consumption and its predictors, CD and UC show a different behaviour. Future studies on health resource consumption should analyse CD and UC separately.
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